GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Neovasc Inc (NAS:NVCN) » Definitions » Net Interest Income

Neovasc (Neovasc) Net Interest Income : $-5.35 Mil (TTM As of Dec. 2022)


View and export this data going back to 2008. Start your Free Trial

What is Neovasc Net Interest Income?

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. Neovasc's net interest income for the three months ended in Dec. 2022 was $-4.35 Mil. Its net interest income for the trailing twelve months (TTM) ended in Dec. 2022 was $-5.35 Mil.


Neovasc Net Interest Income Historical Data

The historical data trend for Neovasc's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neovasc Net Interest Income Chart

Neovasc Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.18 0.05 -3.14 -9.15 -5.35

Neovasc Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Net Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.35 -0.33 -0.34 -0.32 -4.35

Neovasc Net Interest Income Calculation

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.

Net Interest Income for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.35 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neovasc Net Interest Income Related Terms

Thank you for viewing the detailed overview of Neovasc's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Neovasc (Neovasc) Business Description

Traded in Other Exchanges
N/A
Address
13562 Maycrest Way, Suite 5138, Richmond, BC, CAN, V6V 2J7
Neovasc Inc is a specialty medical device company. It develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products the Neovasc Reducer (Reducer), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. The company earns revenue from one source, the Reducer.

Neovasc (Neovasc) Headlines

From GuruFocus

Neovasc Announces Direct Sales Operations in United Kingdom

By GuruFocusNews GuruFocusNews 07-05-2022

Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule

By GuruFocusNews GuruFocusNews 06-25-2022

Neovasc to Participate in H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 06-12-2022

Neovasc Announces Progress on COSIRA-II Clinical Trial

By Value_Insider Value_Insider 11-28-2022

Neovasc to Report Third Quarter Financial Results on November 10, 2022

By Value_Insider Value_Insider 10-27-2022

Neovasc Reducer Obtains U.S. Outpatient Reimbursement

By Value_Insider Value_Insider 11-08-2022